Bicalutamide

CHEMBL409 Phase 4 Aprovado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

430.4 g/mol

LogP

2.3

Phase

4

A non-steroidal antiandrogen used primarily in the treatment of prostate cancer by blocking testosterone's ability to stimulate cancer cell growth. It is taken orally and is often combined with other hormonal therapies. Side effects include hot flashes, breast tenderness, and reduced libido.

Peso Molecular

430,4000 g/mol

LogP

2,30

TPSA

116,00 Å²

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Respiratory Disease Non-Small Cell Lung Cancer Osteoporosis Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Infectious Disease Gastroesophageal Reflux Disease Inflammatory Bowel Disease Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Lymphoma Hypertension Breast Cancer HIV/AIDS Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estrutura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1

InChI

InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)

Molecular Formula

C18H14F4N2O4S

HBD / HBA

2 / 9

Ligações Rotacionáveis

5

Átomos Pesados

29

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

A non-steroidal antiandrogen used primarily in the treatment of prostate cancer by blocking testosterone's ability to stimulate cancer cell growth. It is taken orally and is often combined with other hormonal therapies. Side effects include hot flashes, breast tenderness, and reduced libido.

Yes, Bicalutamide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL409. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 2375. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Procura informações acessíveis para o paciente?

Bicalutamide no PillFYI

Estrutura

Dados Rápidos

Fórmula: C18H14F4N2O4S
Sinônimos: 1

Links Externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.